These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

559 related items for PubMed ID: 16470484

  • 1. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK.
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
    Wade VL, Gleason BL.
    Ann Pharmacother; 2004 Sep; 38(7-8):1278-82. PubMed ID: 15187210
    [Abstract] [Full Text] [Related]

  • 4. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
    Fernandez-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J.
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR, Romero B, Fernandez-Carbonero E, Sánchez-Casado E, Cubero JJ.
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [Abstract] [Full Text] [Related]

  • 6. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 7. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L, Kocks MJ, Laverman GD, Navis G.
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [Abstract] [Full Text] [Related]

  • 8. Preventing end stage renal disease in diabetic patients--genetic aspect (part I).
    Jacobsen PK.
    J Renin Angiotensin Aldosterone Syst; 2005 Mar; 6(1):1-14. PubMed ID: 16088846
    [Abstract] [Full Text] [Related]

  • 9. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
    Cantarovich F, Rangoonwala B.
    Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
    [Abstract] [Full Text] [Related]

  • 11. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN.
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [Abstract] [Full Text] [Related]

  • 12. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB, Coffman TM.
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [Abstract] [Full Text] [Related]

  • 13. Losartan in diabetic nephropathy.
    Perico N, Ruggenenti P, Remuzzi G.
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [Abstract] [Full Text] [Related]

  • 14. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA, Onuigbo NT.
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB, Britton ML.
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [Abstract] [Full Text] [Related]

  • 16. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
    Hollenberg NK, Epstein M.
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325
    [No Abstract] [Full Text] [Related]

  • 17. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B.
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [Abstract] [Full Text] [Related]

  • 18. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM.
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [Abstract] [Full Text] [Related]

  • 19. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
    Böger CA, Götz AK, Krüger B, Hösl M, Schmitz G, Riegger GA, Krämer BK.
    Eur J Med Res; 2005 Apr 20; 10(4):161-8. PubMed ID: 15946912
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED, Preddie DC.
    Ethn Dis; 2002 Apr 20; 12(4):S3-49-52. PubMed ID: 12477155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.